HI
ADAP

Harbour Investments’s Adaptimmune Therapeutics ADAP Stock Holding History

Harbour Investments’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-200
Closed – – 2995
2022
Q3 		$0 Hold
200
– – ﹤0.01% 2709
2022
Q2 		$0 Buy
+200
New +$344 ﹤0.01% 2709
2021
Q4 		$1K Sell
200
-25
-11% -$114 ﹤0.01% 2467
2021
Q3 		$1K Hold
225
– – ﹤0.01% 3420
2021
Q2 		$1K Buy
225
+200
+800% +$971 ﹤0.01% 3482
2021
Q1 		$0 Buy
+25
New +$143 ﹤0.01% 3580

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Harbour Investments's ADAP Position: Q4 2022 in Review

Harbour Investments sold out of Adaptimmune Therapeutics (ADAP) in Q4 2022, closing a stake of 200 shares.

Harbour Investments first reported a position in ADAP in Q1 2021 and held it in 6 quarters. The position peaked at $1K in Q4 2021. 69 funds tracked by Wall St. Rank hold ADAP as of Q4 2022.

  • Harbour Investments reported no remaining Adaptimmune Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Harbour Investments sold 200 Adaptimmune Therapeutics shares in Q4 2022.
  • Harbour Investments first reported a position in Adaptimmune Therapeutics in Q1 2021 and held it in 6 quarters.
  • Harbour Investments's Adaptimmune Therapeutics position peaked at $1K in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2022.

Based on Harbour Investments's 13F filing for Q4 2022, filed 16 Feb 2023.